Jason's article re. AMBS is overall an interesting read, but his estimates re. LYMPRO seem odd, almost intentionally stated in a way to disparage investors who have obviously been placing huge hopes on possible revenue streams from that source. I found his essay re. Eltoprazine interesting, and perhaps very much on target in terms of the potential it brings to the PD market as well as ADHD and other indications as well.
But over and above the interesting points that he made, I seem to remember very clearly that his previous blogs had very little affect on the pps anyway, regardless of how positive he was. We will see, but I have come to the point, that I take what he has to say with a "grain of salt." Gerald's statements regarding up coming events have not changed, and I'm looking forward to milestone achievements in the coming days and weeks.